Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX +0.85%60 EV-to-OCF is 21.54 as of Aug. 13, 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.83 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 78.55% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aroa Biosurgery's Enterprise Value is A$189.42 Mil.
Aroa Biosurgery's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$8.79 Mil. Therefore, Aroa Biosurgery's EV-to-OCF for today is 21.54.
The historical rank and industry rank for Aroa Biosurgery's EV-to-OCF or its related term are showing as below:
ASX:ARX'
s EV-to-OCF Range Over the Past 10 Years
Min: -108.49 Med: -49.37 Max: 26.58
Current: 21.3
During the past 7 years, the highest EV-to-OCF of Aroa Biosurgery was 26.58. The lowest was -108.49. And the median was -49.37.
ASX:ARX's EV-to-OCF is ranked worse than 78.55% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.88
vs ASX:ARX: 21.30
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aroa Biosurgery's PE Ratio (TTM) for today is calculated as:
Aroa Biosurgery's share price for today is A$0.59.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aroa Biosurgery EV-to-OCF Related Terms
Aroa Biosurgery EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's EV-to-OCF falls into.
Aroa Biosurgery's current Enterprise Value is A$189.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$8.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a EV-to-OCF of 21.54 as of Aug. 13, 2026. According to the industry distribution chart, Aroa Biosurgery ranks #670 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 78.5%.
Is Aroa Biosurgery's EV-to-OCF too high?
Aroa Biosurgery's current EV-to-OCF is 21.54. The Medical Devices & Instruments industry median EV-to-OCF is 7.88. Aroa Biosurgery's value of 21.54 is 173.4% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #670 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #670 out of 853 companies for EV-to-OCF. This places Aroa Biosurgery in the lower half of its industry. The industry median EV-to-OCF is 7.88. Aroa Biosurgery's value of 21.54 is 173.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.88, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current EV-to-OCF of 21.54 is 173.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current EV-to-OCF is 21.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.83, compared to a current price of A$0.59 — trading 28.9% below its estimated fair value. The current EV-to-OCF is 21.54 and 173.4% above the Medical Devices & Instruments industry median of 7.88. Aroa Biosurgery's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current EV-to-OCF is 21.54 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 28.9% below its estimated GF Value™ of A$0.83.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
EV-to-OCF: 21.54
GF Value™: A$0.83 vs. price of A$0.59 (28.9% below fair value)
Industry Position: 173.4% above the Medical Devices & Instruments median (#670 of 853)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score
Get the complete analysis for ASX:ARX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
